Approved for To treat adults with relapsed or refractory AML with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. 12.1 Mechanism of Action Ziftomenib is a menin inhibitor that blocks the interaction of menin and lysine [K]-specific methyltransferase 2A (KMT2A). Acute leukemias can be driven by mutations in NPM1… Side effects, costs, interactions, manufacturer,…
Loading full data from Know Your Drugs Institute…